Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757836 | 0.93 | CHRNB4 (0.40) | CHRNB4CHRNA3SMN1; SMN2FFAR4ALDH1A1 | |
| SCHEMBL759473 | 0.93 | CHRNB4 (0.43) | CHRNB4CHRNA3SMN1; SMN2TSHRNR1H4 | |
| SCHEMBL30484265 | 0.78 | DHFR (0.48) | SMN1; SMN2TSHRFFAR4ALDH1A1HTT | |
| SCHEMBL757234 | 0.78 | P2RX3 (0.49) | SMN1; SMN2FFAR4ALDH1A1HTTP2RX3 | |
| SCHEMBL112105 | 0.78 | DHFR (0.48) | SMN1; SMN2TSHRFFAR4ALDH1A1HTT | |
| SCHEMBL27688854 | 0.76 | TAAR1 (0.46) | SMN1; SMN2TSHRNR1H4ALDH1A1HTT | |
| SCHEMBL16902897 | 0.75 | TSHR (0.47) | SMN1; SMN2TSHRNR1H4TAAR1MTNR1B | |
| SCHEMBL13803109 | 0.72 | TSHR (0.45) | SMN1; SMN2TSHRNR1H4ALDH1A1TAAR1 | |
| SCHEMBL4683209 | 0.72 | ACACB (0.47) | SMN1; SMN2TSHR | |
| SCHEMBL16902900 | 0.72 | TSHR (0.49) | SMN1; SMN2TSHRNR1H4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | CHRNB4 616/4885CHRNA3 639/4885SMN1; SMN2 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.